Evaluation of the neuroprotective effect of metformin in diabetic patients with glaucoma
Abstract Purpose: Metformin, a biguanide used to treat diabetes, reduced neuroinflammation in vitro and in vivo and resulted neuroprotective in experimental Parkinson's disease. Metformin has also recently been shown to promote neurogenesis (1). The study aims to evaluate the putative neuroprotective effect of metformin in glaucomatous diabetic patients. Methods: For this retrospective pilot study, clinical notes of glaucomatous diabetic patients of the ophthalmological department of the University Hospital of Rome Tor Vergata were reviewed. Among all, 15 patients were compliant with the inclusion criteria. Patients were then divided into 2 sub‐groups: the Glaucoma group treated with metformin ( n = 16 eyes) and the Glaucoma group treated with insulin ( n = 14 eyes). Any glaucoma treatment was accepted with exception of brimonidine, citicoline, and coenzyme Q10. Patients must have performed in their clinical history two 24‐2 visual field examinations carried out 6 months apart. Results: Patients were homogeneous in terms of age ( p = 0.09) and gender ( p > 0.73). Metformin and Insulin groups were homogeneous in terms of Mean Deviation (MD) and Pattern Standard Deviation (PSD) at baseline (T0) ( p = 0.70 and p = 0.73 respectively). After 6 months (T1) MD did not change significantly in the metformin group ( p = 0.64). On the contrary, at T1 MD significantly worsened in the Insulin group ( p = 0.01). No difference was found in terms of PSD in both groups. The visual field Index did not change in the Metformin group while significantly worsened in the Insulin group ( p = 0.03). Conclusions: This study suggests for the first time a possible neuroprotective effect of metformin in glaucomatous diabetic patients. Patients under Metformin did not show a worsening of the visual field test in 6 months. Conversely, patients under Insulin worsened. Other prospective are required to confirm our results. Reference1. Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Front Endocrinol (Lausanne). 2018; 9: 400. doi:10.3389/fendo.2018.00400. PMID: 30072954; PMCID: PMC6060268..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Acta Ophthalmologica - 100(2022) |
| Beteiligte Personen: |
Martucci, Alessio [VerfasserIn] |
|---|
| Anmerkungen: |
Copyright © 2022 Acta Ophthalmologica Scandinavica Foundation |
|---|
| Umfang: |
1 |
|---|
| doi: |
10.1111/j.1755-3768.2022.0216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002201461 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002201461 | ||
| 003 | DE-627 | ||
| 005 | 20231111125731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1755-3768.2022.0216 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_AOS_2022_100_S275.zip.xml |
| 035 | |a (DE-627)WLY002201461 | ||
| 035 | |a (WILEY)AOS0216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Martucci, Alessio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the neuroprotective effect of metformin in diabetic patients with glaucoma |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2022 Acta Ophthalmologica Scandinavica Foundation | ||
| 520 | |a Abstract Purpose: Metformin, a biguanide used to treat diabetes, reduced neuroinflammation in vitro and in vivo and resulted neuroprotective in experimental Parkinson's disease. Metformin has also recently been shown to promote neurogenesis (1). The study aims to evaluate the putative neuroprotective effect of metformin in glaucomatous diabetic patients. Methods: For this retrospective pilot study, clinical notes of glaucomatous diabetic patients of the ophthalmological department of the University Hospital of Rome Tor Vergata were reviewed. Among all, 15 patients were compliant with the inclusion criteria. Patients were then divided into 2 sub‐groups: the Glaucoma group treated with metformin ( n = 16 eyes) and the Glaucoma group treated with insulin ( n = 14 eyes). Any glaucoma treatment was accepted with exception of brimonidine, citicoline, and coenzyme Q10. Patients must have performed in their clinical history two 24‐2 visual field examinations carried out 6 months apart. Results: Patients were homogeneous in terms of age ( p = 0.09) and gender ( p > 0.73). Metformin and Insulin groups were homogeneous in terms of Mean Deviation (MD) and Pattern Standard Deviation (PSD) at baseline (T0) ( p = 0.70 and p = 0.73 respectively). After 6 months (T1) MD did not change significantly in the metformin group ( p = 0.64). On the contrary, at T1 MD significantly worsened in the Insulin group ( p = 0.01). No difference was found in terms of PSD in both groups. The visual field Index did not change in the Metformin group while significantly worsened in the Insulin group ( p = 0.03). Conclusions: This study suggests for the first time a possible neuroprotective effect of metformin in glaucomatous diabetic patients. Patients under Metformin did not show a worsening of the visual field test in 6 months. Conversely, patients under Insulin worsened. Other prospective are required to confirm our results. Reference1. Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Front Endocrinol (Lausanne). 2018; 9: 400. doi:10.3389/fendo.2018.00400. PMID: 30072954; PMCID: PMC6060268. | ||
| 700 | 1 | |a Carlucci, Federico |4 aut | |
| 700 | 1 | |a Satriano, Andrea |4 aut | |
| 700 | 1 | |a Cesareo, Massimo |4 aut | |
| 700 | 1 | |a Russo, Rossella |4 aut | |
| 700 | 1 | |a Nucci, Carlo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta Ophthalmologica |g 100(2022) |w (DE-627)WLY00217877X |x 17553768 |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2022 |g extent:1 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2022 |g 1 | ||